COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00083928
Recruitment Status : Completed
First Posted : June 7, 2004
Last Update Posted : January 24, 2013
Information provided by:
Ångstrom Pharmaceuticals

Brief Summary:
The purpose of this study is to determine whether injections of Å6 are effective in treating ovarian cancer patients who have completed first-line therapy and currently have no detectable cancer but have experienced a doubling of CA 125 levels.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Primary Peritoneal Carcinoma Drug: Å6 subcutaneous injection Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-Blind Trial of the Clinical Activity and Safety of Å6 in Patients With Asymptomatic CA125 Progression of Epithelial Ovarian Cancer After First-Line Chemotherapy
Study Start Date : May 2004
Actual Primary Completion Date : February 2006
Actual Study Completion Date : December 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females ≥18 years of age
  • Histologically or cytologically documented primary epithelial ovarian carcinoma, cancer of the Fallopian tube, or primary peritoneal carcinoma
  • Completion of first-line chemotherapy
  • Clinical remission as a result of chemotherapy
  • History of normal CA125 level after initial course of therapy
  • CA125 serum level has shown 2 consecutive rises based on 3 consecutive samples which are mutually >= 28 days apart, provided that:

    1. the 3rd sample is above the institution's ULN, and
    2. the 3rd sample is confirmed by a 4th sample which is likewise higher than the 2nd sample value and is above the institution's ULN
  • No clinically evident disease progression, as assessed by history, physical examination, computed tomographic (CT) scan, or magnetic resonance imaging (MRI)
  • ECOG Performance Status of 0 or 1
  • No clinically significantly abnormal clinical laboratory tests or concomitant illnesses
  • Ability and willingness to self-administer subcutaneous injections
  • Although pregnancy is extremely unlikely in this patient population because of the disease and prior treatment, patients who have the potential to become pregnant must have a negative pregnancy test and must agree to practice an effective method of contraception throughout the trial.

Exclusion Criteria:

  • Persistent adverse events due to agents administered more than 4 weeks earlier
  • More than 1 course of previous chemotherapy for the qualifying cancer
  • Disease requiring chemotherapy or radiotherapy
  • Ascites
  • Recent history of active infection, gastrointestinal bleeding, thromboembolic disorders, or anticoagulation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00083928

Show Show 24 study locations
Sponsors and Collaborators
Ångstrom Pharmaceuticals
Layout table for additonal information Identifier: NCT00083928    
Other Study ID Numbers: Å6-003
First Posted: June 7, 2004    Key Record Dates
Last Update Posted: January 24, 2013
Last Verified: January 2013
Keywords provided by Ångstrom Pharmaceuticals:
CA125 Progression
ovarian cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type